Page last updated: 2024-09-04

cox 189 and methyldopa

cox 189 has been researched along with methyldopa in 3 studies

Compound Research Comparison

Studies
(cox 189)
Trials
(cox 189)
Recent Studies (post-2010)
(cox 189)
Studies
(methyldopa)
Trials
(methyldopa)
Recent Studies (post-2010) (methyldopa)
16349473,719420143

Protein Interaction Comparison

ProteinTaxonomycox 189 (IC50)methyldopa (IC50)
Epidermal growth factor receptorHomo sapiens (human)5.228
Tyrosine-protein kinase FynHomo sapiens (human)5.176
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)2.126

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ekins, S; Williams, AJ; Xu, JJ1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for cox 189 and methyldopa

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

2 other study(ies) available for cox 189 and methyldopa

ArticleYear
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011